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Abstract
Glioblastomas are the most common and deadliest form of malignant primary brain tumor. Until
recently, therapies for tumors that recur after standard treatment have been largely ineffective.
Recent phase II studies with the humanized monoclonal antibody against vascular endothelial growth
factor bevacizumab suggest that this agent is active in recurrent glioblastomas, producing response
rates of 26-40% and prolonging 6-month progression-free survival to 36-50%. As a result of these
studies, the US Food and Drug Administration recently granted accelerated approval for bevacizumab
as a treatment for recurrent glioblastomas.
Introduction and context
Glioblastomas are the most common malignant primary
brain tumor, with an annual incidence of approximately
3-4 per 100,000 [1]. Standard therapy involves maximal
surgical resection, followed by radiotherapy, together
with concomitant and adjuvant temozolomide [2,3].
Unfortunately, despite these therapies, glioblastomas
inevitably recur with a median time-to-progression of 6.9
months [3]. Following recurrence, the 6-month progres-
sion-free survival (PFS6) is only 9-16% [4-6], and
median survival is approximately 5-7 months [4,5].
Therapy for recurrent glioblastomas may involve surgery,
reirradiation, chemotherapy, or novel agents, including
antiangiogenic therapies [7]. Until recently, these thera-
pies were largely ineffective. Reoperation has a role in a
minority of patients but rarely prolongs survival [8,9].
The role of radiotherapy for recurrent glioblastomas is
controversial [10]. Some reports suggest that fractionated
stereotactic reirradiation [11] and stereotactic radio-
surgery [12] may be beneficial, but selection bias may
have influenced these results. Chemotherapy wafers and
conventional chemotherapies have only limited activity.
Nitrosoureas such as lomustine produce PFS6 rates of
approximately 19% [7,13]. Dose-dense or metronomic
regimens of temozolomide may also have modest
activity in patients who fail standard temozolomide
therapy [14,15].
Recent advances
There has been significant progress in understanding the
molecular pathogenesis of glioblastomas in recent years
[16-18]. This has resulted in increasing interest in the
therapeutic potential of targeted molecular therapies
[2,19]. Unfortunately, the results with single agents
inhibiting receptor tyrosine kinases such as the epider-
mal growth factor receptor and platelet-derived growth
factor (PDGF) receptor or with signal transduction
pathway components such as mammalian target of
rapamycin have been disappointing [19,20]. Reasons
for these poor results include co-activation of multiple
tyrosine kinases [21] and redundant signaling pathways,
limiting the activity of single agents. In addition,
penetration of many agents across the blood-brain
barrier is poor and is compounded by active efflux of
drugs via P-glycoprotein and other pumps. Attempts to
define subsets of patients who respond to specific agents
have also met with limited success [22-24]. Strategies to
improve on the effectiveness of targeted agents using
multitargeted agents that inhibit several kinases, combi-
nations of agents inhibiting complementary targets,
combinations of targeted agents with radiotherapy and
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common pathways are in progress [25].
In contrast to the disappointing results with targeted
therapies directed at tumor cells, there has been
significant progress with agents that inhibit angiogenesis.
Glioblastomas are very vascular tumors and represent a
particularly attractive target for this therapeutic strategy.
These tumors secrete a variety of angiogenic factors such
as vascular endothelial growth factor (VEGF), PDGF, and
basic fibroblast growth factor (bFGF), which contribute
to neovascularization [26]. In addition, VEGF is an
important cause of the increased vascular permeability
and peritumoral edema that contribute significantly to
the morbidity associated with these tumors [26].
The recent availability of potent antiangiogenic agents
targeting VEGF and its receptors (VEGFR) has led to
important progress in the treatment of glioblastomas
[26,27]. Bevacizumab, a humanized monoclonal anti-
body that binds VEGF, preventing it from activating its
receptors (especially VEGFR2) and abrogating subsequent
biologic effects, has been evaluated alone and in
combination with various chemotherapeutic agents in
recurrent glioblastomas with encouraging results. In an
early phase II study, the combination of bevacizumab and
irinotecan produced a response rate of 57% and a PFS6 of
46% in recurrent glioblastomas [28]. Although the high
‘response rates’ may be partly the result of reduced
vascular permeability and contrast enhancement as a
result of VEGF inhibition, the improvement in PFS6
suggests that there is also a real antitumor effect. The
regimenwas generally well tolerated, witha low incidence
of intracerebral hemorrhage. These preliminary findings
were confirmed by a multicenter randomized phase II
study of 167 patients with recurrent glioblastomas who
were treated with bevacizumab alone or in combination
with irinotecan [29]. Patients receiving bevacizumab
alone had a response rate of 28.2% and a PFS6 of
42.6%, whereas patients receiving bevacizumab in com-
binationwithirinotecan had aresponserate of37.8% and
a PFS6 of 50.3% [29]. In reviewing this trial for purposes
of approval, the US Food and Drug Administration (FDA)
analyzed data from the bevacizumab monotherapy arm
only and determined that the response rate was 26%
and the PFS6 was 36% [30]. Median survival was similar
between the two groups, 9.2 months for bevacizumab
(Avastin®) alone and 8.7 months for the combination,
making it unclear whether the use of irinotecan provided
any additional benefit. Patients treated with bevacizumab
experienced a significant reduction in peritumoral edema
and the need for corticosteroids. This study again
confirmed that bevacizumab was well tolerated, with a
low incidence of intracranial hemorrhage.
A second phase II trial of bevacizumab monotherapy was
conducted in 48 heavily pretreated recurrent glioblas-
toma multiforme patients [31]. The investigators deter-
mined that the response rate was 35%, PFS6 29%, and
median overall survival 31 weeks. On FDA review, the
response rate was 19.6% [30]. Fifty-eight percent of
patients reduced their corticosteroid doses by an average
of 59% [31]. As a result of these two studies, on 5 May
2009 the FDA granted accelerated approval for bevaci-
zumab for the treatment of patients with recurrent
glioblastomas.
Since antiangiogenic agents can potentially have syner-
gistic effects with radiotherapy, there is significant
interest in combining these agents with radiotherapy
[32]. Two phase III trials evaluating the benefits of
adding bevacizumab to radiotherapy and temozolomide
for the treatment of newly diagnosed glioblastomas are
in progress. These studies will help determine the safety
of bevacizumab in newly diagnosed glioblastomas and
whether it is more effective as first-line treatment or at
recurrence.
In addition to bevacizumab, other agents that bind
VEGF, such as aflibercept (VEGF-Trap [33]), are under
active investigation. There is also significant interest in
inhibitors of VEGFR such as cediranib [34], vandetanib,
sorafenib, sunitinib, pazopanib, and CT322 in glioblas-
tomas. In comparison with drugs targeting VEGF or
VEGFR, agents inhibiting other angiogenic pathways
have been less successful. Cilengitide, a drug that inhibits
avb3 and avb5 integrins, has shown modest activity in
glioblastomas, and studies combining it with other
agents are in progress [19,35].
As experience with antiangiogenic agents accumulates, it
is clear that the benefits are only transient, and most
tumors eventually progress after a number of months. In
a subset of patients, these tumors recur not as enhancing
masses, but with a more infiltrative phenotype resem-
bling gliomatosis [36]. This raises the possibility that, by
inhibiting angiogenesis, anti-VEGF and anti-VEGFR
agents force tumor cells to co-opt and grow along
existing blood vessels, changing their natural history
[37,38]. Unfortunately, most of the conventional thera-
pies are generally ineffective for patients who progress on
bevacizumab and subsequent survival is often limited
[39]. As a result, it is unclear whether the improvements
in progression-free survival produced by these agents
translate into a significant increase in overall survival
[40]. To improve on the advances made with bevacizu-
mab and other anti-VEGF/VEGFR agents, it will be
critical to identify the mechanisms that determine
intrinsic resistance of subsets of glioblastomas to these
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therapy which allow the tumor to eventually progress
after an initial response. These mechanisms of resistance
are thought to include upregulation of alternative
proangiogenic signals such as bFGF leading to revascu-
larization, protection of the tumor vasculature either
by recruiting proangiogenic inflammatory cells or by
increasing protective pericyte coverage, as well as co-
option of normal vasculature and invasion into sur-
rounding tissue [41]. Combining agents targeting VEGF
with inhibitors of other angiogenic molecules such as
bFGF or with drugs that inhibit invasion may hold
promise. Other novel therapies undergoing evaluation
for glioblastomas include viral gene therapies [42,43],
immunotherapies [44], and convection-enhanced deliv-
ery of targeted immunotoxins [45], but their value
remains to be determined.
Implications for clinical practice
After over two decades of minimal progress in the
treatment of recurrent glioblastomas, bevacizumab
represents an important but limited advance. This
agent undoubtedly increases progression-free survival
and improves quality of life, but how much it prolongs
survival remains unclear. Whether the drug should be
used alone or in combination with chemotherapeutic
agents and which ones should be used also remain
unclear. Although most of the studies have been
performed with irinotecan, it is possible that combining
bevacizumab with lomustine may be more effective. It is
also unclear whether bevacizumab should be used at first
relapse or whether patients should be treated with other
therapies or enrolled into clinical trials first and
bevacizumab reserved for subsequent progression.
Given the difficulty in evaluating agents after bevacizu-
mab failure, it seems prudent to evaluate these agents
first in bevacizumab-naïve patients.
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